Group One Trading
ARQT icon

Group One Trading’s Arcutis Biotherapeutics ARQT Stock Holding History

Group One Trading’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,338
Closed -$75.2K – 7552
2024
Q4 		$74.4K Buy
+5,338
New +$58.5K ﹤0.01% 4764
2024
Q2 		– Sell
-60,347
Closed -$546K – 6678
2024
Q1 		$598K Buy
60,347
+8,661
+17% +$64.6K ﹤0.01% 2559
2023
Q4 		$167K Buy
+51,686
New +$141K ﹤0.01% 4023
2023
Q3 		– Sell
-3,379
Closed -$28.7K – 7618
2023
Q2 		$32.2K Buy
+3,379
New +$37.5K ﹤0.01% 5627

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading's ARQT Position: Q1 2025 in Review

Group One Trading sold out of Arcutis Biotherapeutics (ARQT) in Q1 2025, closing a stake of 5,338 shares — an estimated $75.2K sold.

Group One Trading first reported a position in ARQT in Q2 2023 and held it in 4 quarters. The position peaked at $598K in Q1 2024. 241 funds tracked by Wall St. Rank hold ARQT as of Q1 2025.

  • Group One Trading reported no remaining Arcutis Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Group One Trading sold 5,338 Arcutis Biotherapeutics shares in Q1 2025, an estimated $75.2K.
  • Group One Trading first reported a position in Arcutis Biotherapeutics in Q2 2023 and held it in 4 quarters.
  • Group One Trading's Arcutis Biotherapeutics position peaked at $598K in Q1 2024.
  • 241 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2025.

Based on Group One Trading's 13F filing for Q1 2025, filed 14 May 2025.